Pasithea Therapeutics Corp.
NASDAQ Capital MarketTotal Valuation
Pasithea Therapeutics Corp. carries a market capitalization of 19.38M, placing it among publicly traded companies globally. Its enterprise value stands at -31.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.38M |
| Enterprise Value | -31.90M |
Share Statistics
Pasithea Therapeutics Corp. currently has 24.94M shares outstanding.
| Shares Outstanding | 24.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.36 |
| P/FCF Ratio | -0.55 |
| P/OCF Ratio | -0.55 |
Financial Position
Pasithea Therapeutics Corp. maintains a current ratio of 35.40, meaning it holds 35.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 35.40 |
| Quick Ratio | 33.84 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -58.22 |
| Return on Assets (ROA) | -55.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Pasithea Therapeutics Corp.'s stock has declined approximately -26.60086% over the past 52 weeks. The 50-day moving average sits at 0.50, while the 200-day moving average is 0.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.60086% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.74 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -21.40M, while operating income came in at -22.05M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -22.05M |
| Pretax Income | -19.73M |
| Net Income | -19.73M |
| EBITDA | -21.40M |
| EBIT | -22.05M |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
Total book value stands at 54.81M, with working capital of 51.24M providing operational flexibility.
| Cash & Cash Equivalents | 50.40M |
| Total Debt | N/A |
| Net Debt | -50.40M |
| Equity (Book Value) | 54.81M |
| Book Value Per Share | 2.20 |
| Working Capital | 51.24M |
Cash Flow
Pasithea Therapeutics Corp. produced -16.94M in operating cash flow over the past twelve months.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | N/A |
| Free Cash Flow | -16.94M |
| FCF Per Share | -1.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -335.37 |
| FCF Yield | -183.10 |
Stock Splits
Pasithea Therapeutics Corp.'s most recent stock split took place on January 2, 2024 with a 20:1 split ratio.
| Last Split Date | 1/2/2024 |
| Split Ratio | 20:1 |
Scores
Pasithea Therapeutics Corp. posts an Altman Z-Score of 5.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.05 |